Novel C-aryl glucoside SGLT2 inhibitors containing triazine motif were designed and synthesized for biological evaluation. Among the compounds assayed, triazine containing methoxy moiety 18 demonstrated the best in vitro inhibitory activity against hSGLT2 in this series to date (IC50 = 24.9 nM).
Introduction
Diabetes has become an increasing concern to the world's population. In 2007, approximately 246 million people were considered diabetic, with an additional 7 million people diagnosed with the disease every year. Type 2 diabetes is the most common disorder of glucose homeostasis, answering for almost 90-95% of all cases of diabetes.
Sodium-dependent glucose cotransporters (SGLTs) couple the transport of glucose against a concentration gradient with the simultaneous transport of Na + down a concentration gradient. It is believed that 90% of renal glucose reuptake is facilitated by SGLT2. Bristol-Myers Squibb has identified dapagliflozin 1, a potent, selective SGLT2 inhibitor for the treatment of type 2 diabetes (Figure 1 ). Currently, dapagliflozin is the most advanced SGLT2 inhibitor in clinical trials. On the other hand, Mitsubishi Tanabe, in collaboration with Johnson & Johnson, is developing canagliflozin 2, another novel C-glucoside-derived SGLT2 inhibitor. In addition, several compounds originated from Boehringer Ingelheim, Lexicon, Astellas, and Pfizer are reported to be in various phase of clinical trials, respectively.
In the present study, C-glucosides bearing a heteroaromatic ring were exploited in order to develop novel SGLT2 targeting antidiabetic agents. We envisioned that replacement of the distal ring of dapagliflozin 1 with a heterocyclic ring might improve the physicochemical properties, thereby providing a high possibility for clinical development. Along this line, the structure of dapagliflozin was modified into proposed structure 5, bearing a 1,2,4-triazine or fused 1,2,4-triazine ring as shown in Figure 2 . Herein, we report the design, synthesis and biological evaluation of triazinylmethylphenyl glucoside congeners. Cloning and Cell Line Construction for Human SGLT2. Human SGLT2 (hSGLT2) gene was amplified by PCR from cDNA-Human Adult Normal Tissue Kidney (Invitrogen, Carlsbad, CA). The hSGLT2 sequence was cloned into pcDNA3.1(+) for mammalian expression and were stably transfected into Chinese hamster ovary (CHO) cells. SGLT2-expressing clones were selected based on resistance to G418 antibiotic (Geneticin®, Invitrogen, Carlsbad, CA) and activity in the Inhibitory Effects on Human SGLT2 Activities. For sodium-dependent glucose transport assay, cells expressing hSGLT2 were seeded into a 96-well culture plate at a density of 5 × 10 4 cells/well in RPMI medium 1640 containing 10% fetal bovine serum. The cells were used 1 day after plating. They were incubated in pretreatment buffer (10 mM HEPES, 5 mM Tris, 140 mM choline chloride, 2 mM KCl, 1 mM CaCl 2 , and 1 mM MgCl 2 , pH 7.4) at 37 °C for 10 min.
They were then incubated in uptake buffer (10 mM HEPES, 5 mM Tris, 140 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 1 mM 14 C-nonlabeled AMG pH 7.4) containing 14 C-labeled (8 uM) and inhibitor or dimethyl sulfoxide (DMSO) vehicle at 37 °C for 2 h. Cells were washed twice with washing buffer (pretreatment buffer containing 10 mM AMG at room temperature) and then the radioactivity was measured using a liquid scintillation counter. IC 50 was determined by nonlinear regression analysis using GraphPad PRISM.
Results and Discussion
Preparation of the benzotriazine compound is described in Scheme 1. Thus, coupling of ester 6 2 and 3-chloro-7-methylbenzo[e][1,2,4]triazine 1-oxide (7) 3,4 using NaH in the presence of DMF (N,N-dimethylformamide) produced the corresponding ester 8 in moderate yield (25%, 65% based on starting material recovered), which was reduced using Zn and NH 4 Cl in an aqueous solution of dioxane to generate the ester 9 in 75% yield. Hydrolysis and concomitant decarboxylation using NaOH in a refluxed aqueous solution of methanol and THF (tetrahydrofuran) generated 10 in 73% yield. At last, total removal of benzyl groups using iodotrimethylsilane in the presence of CH 3 CN at ambient temperature produced the target benzotriazine 11 in 52% yield over two steps.
We next extended our synthetic efforts for preparation of a novel triazine analog as shown in Scheme 2. Thus, previously reported carboxylic acid 12 2 was coupled with methyl 2-aminoacetate hydrochloride in the presence of EDCI (1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide), HOBt (1-hydroxybenzotriazole), and NMM (N-methylmorpholine) to provide the corresponding amide 13 in quantitative yield. Amide 13 smoothly underwent hydrazinolysis and subsequent cyclization to afford 14 in 77% yield over two steps. Oxidation of 14 with DDQ (2,3-dichloro-5,6-dicyano-pbenzoquinone) in CH 2 Cl 2 , and subsequent treatment of the resulting 15 with POCl 3 in toluene at 70 o C produced the key intermediate 16 in 35% yield over two steps. The remaining tasks involve introduction of methoxy group at C-6 position of triazine and deprotection of benzyl groups on glucose ring. Initial attempt to install methoxide and subsequent removal of benzyl groups using BCl 3 turned out to be troublesome. However, use of TMSOTf (trimethylsilyl trifluoromethanesulfonate) in combination with acetic anhydride uneventfully provided the peracetate 17. Subsequently, introduction of methoxy group at C-6 position of triazine and removal of acetates on glucose proceeded smoothly (NaOCH 3 , CH 3 OH) to provide the target triazine 18 in one-pot reaction in a high yield (94%).
The cell-based SGLT2 AMG (Methyl-α-D-glucopyranoside) inhibition assay was performed to evaluate the inhibitory effects of all prepared compounds on hSGLT2 activities.
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While the parent dapagliflozin 1 shows highly potent inhibitory activity against hSGLT2 (IC 50 = 0.49 nM), neither of the analog structure results in better inhibitory activity against hSGLT2 (IC 50 = 491 nM for 11 vs IC 50 = 24.9 nM for 18 via in-house assay).
7 Based on this in vitro SGLT2 inhibitory activity data, it is apparent that the nitrogen atoms in the triazinyl moiety are not contributing positively to the inhibitory activity of triazinyl analogs of dapagliflozin. Especially, bicyclic benzotriazine reduces the inhibitory activity against hSGLT2 in two orders of magnitude, suggesting that flat and rigid bicyclic moiety is not tolerant at this region.
Conclusion
In summary, metabolically more stable C-glucosides bearing triazine ring as a potential antidiabetic agent was exploited. Among the compounds tested, triazine containing methoxy moiety 18 showed the better in vitro inhibitory activity against hSGLT2 in this series to date (IC 50 = 24.9 nM). Replacement of the distal ring of dapagliflozin with a triazine ring appears to weaken in vitro inhibitory activity against hSGLT2 in an order of magnitude. However, the information obtained from this triazine series should help to design more effective SGLT2 inhibitors that are structurally related.
